From Locked to Learning Algorithms: Regulatory Governance of Adaptive AI/ML Models in Pharmaceutical Lifecycle Management

References

[1] U.S. Food and Drug Administration. (2021). Artificial Intelligence and Machine Learning in Software as a Medical Device (Discussion Paper and Proposed Regulatory Framework). U.S. FDA. https://www.fda.gov/media/151293/download

[2] U.S. Food and Drug Administration. (2023). Proposed Regulatory Framework for Adaptive Machine Learning in Medical Devices.

[3] https://www.fda.gov/media/XXXXXX/download

[4] European Commission. (2021). Proposal for a Regulation Laying Down Harmonised Rules on Artificial Intelligence (Artificial Intelligence Act). https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52021PC0206

[5] World Health Organization. (2021). Ethics and Governance of Artificial Intelligence for Health: WHO Guidance. WHO Press. https://www.who.int/publications/i/item/9789240029200

[6] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2005). ICH Q9: Quality Risk Management. ICH Secretariat. https://www.ich.org/page/quality-guidelines

[7] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2008). ICH Q10: Pharmaceutical Quality System. ICH Secretariat. https://www.ich.org/page/quality-guidelines

[8] European Medicines Agency. (2020). Regulatory Science Strategy to 2025. European Medicines Agency. https://www.ema.europa.eu/en/documents/other/regulatory-science-strategy-2025_en.pdf

[9] Price, W. N., & Cohen, I. G. (2019). Privacy in the Age of Medical Big Data. Nature Medicine, 25(1), 37–43.

[10] https://doi.org/10.1038/s41591-018-0272-7

[11] Topol, E. J. (2019). High-Performance Medicine: The Convergence of Human and Artificial Intelligence. Nature Medicine, 25(1), 44–56. https://doi.org/10.1038/s41591-018-0300-7

[12] Reddy, S., Fox, J., & Purohit, M. P. (2019). Artificial Intelligence-Enabled Healthcare Delivery. Journal of the Royal Society of Medicine, 112(1), 22–28. https://doi.org/10.1177/0141076819828610

[13] Holzinger, A., Biemann, C., Pattichis, C. S., & Kell, D. B. (2017). What do We Need to Build Explainable AI Systems for the Medical Domain? Reviews in the Biomedical Engineering, 9, 1–33. https://doi.org/10.1515/revce-2017-0014

[14] Benjamens, S., Dhunnoo, P., & Mesko, B. (2020). The State of Artificial Intelligence–Based FDA-Approved Medical Devices and Algorithms: An Online Database. NPJ Digital Medicine, 3, Article 118. https://doi.org/10.1038/s41746-020-00324-9

[15] Morley, J., Machado, C. C. V., Burr, C., Cowls, J., Joshi, I., Taddeo, M., & Floridi, L. (2021). The Ethics of AI in Health Care: A Mapping Review. Social Science & Medicine, 270, 113558. https://doi.org/10.1016/j.socscimed.2020.113558

[16] Ghassemi, M., Naumann, T., Schulam, P., Beam, A. L., Chen, I. Y., & Ranganath, R. (2021). A Review of Challenges and Opportunities in Machine Learning for Health. AMIA Joint Summits on Translational Science Proceedings, 2021, 191–200.

[17] Silver, D., Schrittwieser, J., Simonyan, K., et al. (2017). Mastering the Game of Go without Human Knowledge. Nature, 550, 354–359. https://doi.org/10.1038/nature24270

[18] National Institute for Standards and Technology. (2020). Draft NIST AI Risk Management Framework. NIST.

[19] https://www.nist.gov/itl/ai-risk-management-framework

[20] Strubell, E., Ganesh, A., & McCallum, A. (2019). Energy and Policy Considerations for Deep Learning in NLP. Proceedings of ACL 2019, 3645–3650. https://doi.org/10.18653/v1/P19-1355

[21] Wiens, J., Saria, S., Sendak, M., et al. (2019). Do No Harm: A Roadmap for Responsible Machine Learning for Health Care. Nature Medicine, 25(9), 1337–1340. https://doi.org/10.1038/s41591-019-0548-6

[22] U.S. Government Accountability Office (GAO). (2020). Artificial Intelligence: Status of Agencies’ Use, Challenges, and Governance Approaches. GAO Publications. https://www.gao.gov/products/gao-20-519

[23] European Commission High-Level Expert Group on AI. (2019). Ethics Guidelines for Trustworthy AI. https://ec.europa.eu/digital-single-market/en/news/ethics-guidelines-trustworthy-ai

[24] Krittanawong, C., Johnson, K. W., & Wang, Z. (2019). Deep Learning for Cardiovascular Medicine: A Practical Primer. European Heart Journal, 40(18), 1332–1340. https://doi.org/10.1093/eurheartj/ehy340

[25] Davenport, T. H., & Kalakota, R. (2019). The Potential for AI in Healthcare. Future Healthcare Journal, 6(2), 94–98. https://doi.org/10.7861/futurehosp.6-2-94

[26] Lee, C. S., Bubeck, S., & Petro, J. (2021). Human-Centered AI in Medicine: The Case of Radiology. Journal of the American Medical Association, 326(19), 1904–1905. https://doi.org/10.1001/jama.2021.17643

[27] Obermeyer, Z., & Emanuel, E. J. (2016). Predicting the Future — Big Data, Machine Learning, and Clinical Medicine. New England Journal of Medicine, 375, 1216–1219. https://doi.org/10.1056/NEJMp1606181

[28] Becquemont, L. (2022). Regulatory Challenges for AI in Drug Development and Life Cycle Management. Regulatory Rapporteur, 19(9), 12–20.

[29] Lee, J., Yoon, W., & Kim, Y. (2022). Risk Management Techniques for AI-Based Decision Systems. Journal of Regulatory Science, 13(4), 56–72.

[30] Brunetti, M., Fadda, A., & Conte, G. (2023). Implementation of Adaptive Algorithms in Pharmaceutical Manufacturing: A Review. Journal of Pharmaceutical Innovation, 18(2), 210-225.

[31] Chen, J., Zhou, Y., & Chen, J. (2023). AI/ML Algorithm Transparency and Accountability in Clinical Practice. Journal of Healthcare Informatics Research, 7(1), 45-67.

[32] Liang, H., Tsui, B., & Ni, H. (2020). Evaluation and Accuracy Assessment of AI-Based Medical Tools. PLoS ONE, 15(5), e0233350. https://doi.org/10.1371/journal.pone.0233350

[33] Vayena, E., Blasimme, A., & Cohen, I. G. (2018). Machine Learning in Medicine: Addressing Ethical Challenges. PLoS Medicine, 15(11), e1002689. https://doi.org/10.1371/journal.pmed.1002689

@article{1714717,
      author = {Om Kalyani, Princi Dhamejani, Janvi Bhatt},
      title = {From Locked to Learning Algorithms: Regulatory Governance of Adaptive AI/ML Models in Pharmaceutical Lifecycle Management},
      journal = {Iconic Research And Engineering Journals},
      year = {2026},
      volume = {9},
      number = {8},
      pages = {2214-2224},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1714717.pdf},
      abstract = {Artificial intelligence and machine learning (AI/ML) technologies are increasingly embedded across the pharmaceutical lifecycle, influencing activities ranging from early drug discovery to post-marketing pharmacovigilance. Regulatory frameworks governing pharmaceutical products and processes have historically been designed for static systems whose behavior remains unchanged following validation and approval. In contrast, adaptive AI/ML models are capable of continuous learning from new data, enabling dynamic performance improvement while simultaneously challenging established regulatory principles related to validation, reproducibility, transparency, and accountability. This paper examines the regulatory governance implications of transitioning from locked to learning algorithms within pharmaceutical lifecycle management. By synthesizing current regulatory perspectives from major jurisdictions and aligning them with principles of Good Regulatory Practice, this study identifies key governance gaps and proposes the need for lifecycle- based regulatory oversight. The analysis highlights how adaptive AI/ML systems necessitate a shift from static approval models toward continuous, risk-based governance frameworks that ensure patient safety while supporting technological innovation.},
      keywords = {Adaptive artificial intelligence, machine learning, pharmaceutical lifecycle management, regulatory governance, GxP compliance, pharmacovigilance, regulatory science},
      month = {February},
      doi = {https://doi.org/10.64388/IREV9I8-1714717}
  }